Will the government seek independent patient input on drug policy?

Industry-funded patient-advocacy groups have drowned out the voices of the patient community. In the lead-up to a national pharamcare policy, the government has a chance to change course for the better, writes Sharon Batt.

Prime Minister Justin Trudeau, pictured on Nov. 14, 2019, meeting with New Democratic Party Leader Jagmeet Singh in the prime minister's West Block office. Sharon Batt writes that she is cautiously hopefuly the government 'will jettison a longstanding, dubious practice: soliciting input from patient advocacy groups funded by the pharmaceutical industry.' The Hill Times photograph by Andrew Meade

Opinion

BY SHARON BATT

February 3, 2020

HALIFAX—In the lead-up to some form of national pharmacare, the Trudeau government plans to launch a new national Canadian Drug Agency

To keep reading, subscribe and become a political insider.

Only $7.76 a week for an annual subscription.

Enjoy unlimited website access and the digital newspaper.

Cancel anytime.

Already a Subscriber?

Get Weekend Point of View Newsletter

A round up of the past weekâ€™s opinion writers and columnists on Saturdays and Sundays.

By entering your email address you consent to receive email from The Hill Times containing news, analysis, updates and offers. You may unsubscribe at any time. See our privacy policy